Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nebulized interferon beta-1b plus lopinavir/ritonavir for hospitalized COVID-19
2020-001892-34Phase 2Completed
- Sponsor
- CHU Amiens-Picardie
- Start
- Apr 2020
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2 trial of interferon beta-1b in coronavirus disease 2019 (COVID-19) (2 arms), sponsored by CHU Amiens-Picardie. Primary endpoint: Sustained viral negativation time. Started Apr 2020; status: completed.
02
Drugs
interferon beta-1b
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on 2020-001892-34.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-001892-34.